Yearly zoledronic acid in postmenopausal osteoporosis [1]

New England Journal of Medicine

Volumn 357, Issue 7, 2007, Pages 711-715

  De Nijs, Ron N J ^a   Westgeest, Antonius A A ^a  

^a MÁXIMA MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE; ZOLEDRONIC ACID; CALCIUM; PAMIDRONIC ACID; PLACEBO; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

CLINICAL STUDY; DRUG INFUSION; ELECTROLYTE DISTURBANCE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INCIDENCE; LETTER; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT; VERTEBRA FRACTURE; CALCIUM BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; FEMALE; FRACTURE; NOTE;

ATRIAL FIBRILLATION; BONE DENSITY CONSERVATION AGENTS; CALCIUM; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, BONE; HUMANS; HYPOCALCEMIA; IMIDAZOLES; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE;

EID: 34547933817     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc071514     Document Type: Letter

References (5)

1. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.
2. Sorscher SM. Electrolyte abnormalities with zoledronic acid therapy. Cancer J 2002;8:348-9.
3. Abbott LG, Rude RK. Clinical manifestations of magnesium deficiency. Miner Electrolyte Metab 1993;19:314-22.
4. Whang R, Hampton EM, Whang DD. Magnesium homeostasis and clinical disorders of magnesium deficiency. Ann Pharmacother 1994;28:220-6.
5. Peter R, Mishra V, Fraser WD. Severe hypocalcaemia after being given intravenous bisphosphonate. BMJ 2004;328:335-6.